Insulin Therapy does not Interfere with Venous Endothelial Function Evaluation in Patients with Type 2 Diabetes Mellitus

Antônio Marcos Vargas da Silva,¹ Luciana de Moraes Penno,⃗ Marcello Casaccia Bertoluci,⃗⃗ Maria Cláudia Irigoyen,Ⅳ,Ⅴ Beatriz D’Agord SchaanⅣ,Ⅵ

¹Departamento de Fisioterapia e Reabilitação, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil. ⃗⃗Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil. ⅣUniversidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil. ⅤFaculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. ⅥUnidade de Hipertensão, Instituto do Coração, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

INTRODUCTION:
Endothelium-dependent dilation is improved in insulin-treated diabetic patients, but this effect is probably due to improved glycemic control. The objective of the present study was to compare endothelium-dependent dilation in patients with well-controlled type 2 diabetes who are or are not using insulin as part of their therapy.

METHODS: We studied 27 patients with type 2 diabetes (11 women, 60.3 years ± 6 years, with HbA₁c < 7% and no nephropathy), including 16 patients treated with anti-diabetic agents (No-Ins, 8 women) and 11 patients treated with insulin alone or in combination with anti-diabetic agents (Ins, 3 women). Endothelial function was evaluated by the dorsal hand vein technique, which measures changes in vein diameter in response to phenylephrine, acetylcholine (endothelium-dependent vasodilation) and sodium nitroprusside (endothelium-independent vasodilation).

RESULTS: Age, systolic blood pressure (No-Ins: 129.4 mmHg ± 11.8 mmHg, Ins: 134.8 mmHg ± 12.0 mmHg; P = 0.257), HbA₁c, lipids and urinary albumin excretion rate [No-Ins: 9 mg/24 h (0-14.1 mg/24 h) vs. Ins: 10.6 mg/24 h (7.5-14.4 mg/24 h); P = 0.398] were similar between groups. There was no difference between endothelium-dependent vasodilation of the No-Ins group (59.3% ± 26.5%) vs. the Ins group (54.0% ± 16.3%; P = 0.526). Endothelium-independent vasodilation was also similar between the No-Ins (113.7% ± 35.3%) and Ins groups (111.9% ± 28.5%; P = 0.888).

CONCLUSIONS: Subcutaneous insulin therapy does not interfere with venous endothelial function in type 2 diabetes when glycemic and blood pressure control are stable.

KEYWORDS: Diabetes mellitus, type 2; Diabetes complications; Vascular diseases; Vascular endothelium; Insulin.

Received for publication on July 9, 2010; First review completed on July 29, 2010; Accepted for publication on August 23, 2010
E-mail: beatrizschaan@gmail.com / editoracao.pc@cardiologia.org.br
Tel.: 55 51 3230-3757 / 55 51 3219-2802

INTRODUCTION
The high cardiovascular risk posed by diabetes mellitus (DM) can be attributed to both classic risk factors¹ and also to hyperglycemia and its consequences: oxidative stress and endothelial dysfunction.²,³ These abnormalities are related to insulin resistance, which is detrimental to endothelial function and leads to a pro-inflammatory and pro-coagulant state that plays an important role in mediating atherogenesis and cardiovascular disease.⁵ Diabetes mellitus² and hyperglycemia³ are independent determinants of endothelial dysfunction.

Short-term improvement of glucose control in diabetic patients cannot reverse endothelial dysfunction,⁶,⁷ but long-term treatment of diabetes may be able to achieve this goal.⁸,⁹ It is not known if the treatment of diabetic patients with subcutaneous insulin can interfere with the evaluation of endothelial function. No existing studies have evaluated the possible effect of subcutaneous insulin use on venous endothelial function, a method that, in some instances, can be more sensitive to subtle endothelial abnormalities.¹⁰ The
aim of this study was to compare endothelium-dependent
dilation in patients with type 2 DM with good metabolic
and blood pressure control according to whether they used
insulin as part of their therapy.

METHODS

Patients

We studied 27 patients with type 2 diabetes (11 women; 
age at diagnosis > 35 years old, no previous history of
ketoadosisis, insulin independence for at least 12 months
after diagnosis), including 16 patients treated with diet
alone and/or anti-diabetic agents (No-Ins group) and 11
patients treated with subcutaneous insulin (NPH and/or
regular insulin; 38.2 ± 11.6 U/patient) with or without anti-
diabetic agents (Ins group). Patients were selected from
the outpatients visiting the internal medicine ward of
Irmã da Santa Casa de Misericórdia de Porto Alegre
(ISCMPA) or Hospital de Clínicas de Porto Alegre (HCPA).
We excluded patients older than 70 years and those patients
with high blood pressure levels (systolic arterial pressure
> 180 mmHg and/or diastolic > 100 mmHg); microalbumu-
nuria (24 h urinary albumin ≥ 30 mg/24 h); creatinine >
1.2 mg/dL; body mass index > 30 kg/m²; acute coronary
syndromes; stable angina; current smokers; those patients
under treatment with nitrates or alpha-receptor antagonists;
and/or those patients who were unable to understand and
sign the consent form. The recommended carbohydrate
consumption was limited to 60% of the total caloric intake
for all patients.

Protocol

The protocol was approved by the Research Unit Ethics
Committees at Hospital de Clínicas de Porto Alegre
(HCPA), Universidade Federal de Ciências da Saúde de
Porto Alegre (UFSCSPA) and Irmã da Santa Casa de
Misericórdia de Porto Alegre (ISCMPA), and informed
consent was obtained from each patient. All subjects were
instructed to avoid caffeinated drinks and alcohol for the 12-
h period preceding their appointment. The studies started
about 3 h after the participant consumed a light breakfast.

Dorsal hand vein technique

Venous endothelial function evaluation was performed in
a quiet room at a constant temperature of 21°C ± 1°C.
Venous endothelial function was assessed in all patients via
the dorsal hand vein technique, a method for which our
group has published details elsewhere.10,12,13 Briefly, a 23-
gauge butterfly needle was inserted into a suitable vein on
the back of the hand, and a continuous infusion of
physiologic saline solution (0.3 mL/min) was started. A
tripod holding a linear variable differential transformer
(LVDT; Shaevitz Engineering, Pennsauken, NJ) was
mounted on the hand, with the central aperture of the
LVDT that contained a movable metallic core located 10 mm
downstream from the tip of the needle. The signal output of
the LVDT, which is linearly proportional to the vertical
movement of the core, provided a measurement of the vein
diameter. Readings were taken at a congestive pressure of
40 mmHg by inflating a blood pressure cuff placed on the
upper portion of the arm being studied. The vein was pre-
constricted by infusing increasing doses of the α1-adrener-
gic selective agonist phenylephrine (25 ng/min to 8333.3 ng/
min) until the dose that produced approximately 70%
constriction of the vein was found (ED
2
). This degree of
pre-constriction was defined as 0% venodilation. The
endothelium-dependent venodilation was assessed with
incremental infusions of acetylcholine (3.6 ng/min to
3600 ng/min), and endothelium-independent venodilation
with sodium nitroprusside (495.3 ng/min to 990.6 ng/min)
was calculated as a percentage of the range between 100%
and 0% vasodilation. Drugs were infused with a Harvard
infusion pump (Harvard Apparatus Inc., South Natick,
MA). Blood pressure and heart rate were monitored in the
contra-lateral arm with a sphygmomanometer.

Biochemical measurements

Venous blood and urine samples were obtained during
the morning hours after an overnight fast. Albuminuria was
determined by immunoturbidimetry (MicroAlb; Ames-
Bayer, Tarrytown, NY, USA); plasma glucose was deter-
mined by the glucose-peroxidase colorimetric enzymatic
method (Biodiagnostica, Pinhais, Brazil); and total choles-
terol, HDL cholesterol and triglycerides were determined by
a colorimetric method and HbA1c by high-performance
liquid chromatography (Merck-Hitachi L-9100; Merck,
Darmstadt, Germany). LDL cholesterol was calculated
according to the Friedwald formula. Serum creatinine was
measured by the Jaffé method. Serum insulin was deter-
mined by enzyme immunoassay commercial kits (Abbott-
Murex, Park, IL, USA), and high-sensitivity C-reactive
protein (CRP) was measured by nephelometry.

Statistical analyses

Analyses were performed using SPSS® Base 13.0 (SPSS
Inc., Chicago, IL, USA). The results are presented as the
means ± standard deviations (SD) or medians (25th-75th
percentile). Variables that did not have a Gaussian
distribution (Kolmogorov-Smirnov test) were log10 trans-
formed before additional analyses. Differences between the
groups were tested with unpaired Student’s t-tests and chi-
square tests. The differences were recognized as statistically
significant when P < 0.05.

RESULTS

No differences were observed between the groups
studied concerning age (P = 0.470), body mass index
(P = 0.224) or duration of diabetes (P = 0.142). These and
other clinical and laboratory data are shown in Table 1.
There were no differences between the groups concerning
these characteristics.

Among the 16 patients of the No-Ins group, 10 patients
used statins, 10 patients used aspirin, 10 patients used
diuretics, 13 patients used angiotensin-converting enzyme
inhibitors, 12 patients used metformin, 4 patients used sulfonylurea, and 5 patients used beta-blockers. Among
the 11 patients of the Ins group, 5 patients used statins, 6
patients used aspirin, 6 patients used angiotensin-converting
enzyme inhibitors, 6 patients used metformin, 2 patients
used sulfonylurea, 4 patients used diuretics, and 5 patients
used beta-blockers.

Venous endothelial function data are shown in Table 2.
Endothelium-dependent venodilation (P = 0.526) as mea-
sured for maximum venodilation by acetylcholine, veno-
constriction induced by phenylephrine (P = 0.566) and
venodilation by sodium nitroprusside (endothelium-inde-
pendent venodilation; P = 0.888) were similar between
Table 1 - Baseline clinical and laboratory characteristics by group.

| Parameter                      | No-Ins (n = 16) | Ins (n = 11) | P    |
|--------------------------------|----------------|-------------|------|
| Male (n, %)                    | 8 (50)         | 8 (72.7)    | 0.441|
| Age (years)                    | 59.6 ± 4.8     | 61.3 ± 6.6  | 0.470|
| Weight (kg)                    | 68.3 ± 10.3    | 69.0 ± 15.5 | 0.906|
| BMI (kg/m²)                    | 26.8 ± 1.9     | 25.2 ± 4.0  | 0.224|
| Systolic BP (mmHg)             | 124.9 ± 11.8   | 134.8 ± 12.0| 0.257|
| Diastolic BP (mmHg)            | 81.3 ± 5.3     | 80.9 ± 4.9  | 0.866|
| Heart rate (bpm)               | 69.0 ± 8.9     | 71.5 ± 4.8  | 0.363|
| Diabetes duration (years)      | 6.8 ± 2.5      | 8.4 ± 5.5   | 0.142|
| 24-h albuminuria (mg/24 h)     | 9 (0-14.1)     | 10.6 (7.5-14.4) | 0.398|
| Total cholesterol (mg/dL)      | 161.1 ± 33.6   | 157.2 ± 18.1| 0.715|
| LDL cholesterol (mg/dL)        | 46.9 ± 9.3     | 49.1 ± 11.7 | 0.622|
| Triglycerides (mg/dL)          | 82.8 ± 37.3    | 75.7 ± 30.8 | 0.601|
| Plasma glucose (mg/dL)         | 124.7 ± 17.6   | 130.7 ± 11.6| 0.326|
| HbA1c (%)                      | 6.6 ± 0.6      | 6.9 ± 0.9   | 0.317|
| Insulinemia (µU/mL)            | 9.9 ± 4.3      | 10.8 ± 3.3  | 0.561|
| CRP (mg/L)                     | 2.3 ± 0.8      | 2.1 ± 1.0   | 0.704|
| Creatinine (mg/dL)             | 0.9 ± 0.2      | 0.9 ± 0.1   | 0.729|

Data are means ± SDs or medians (25th-75th percentile) or n (%); BMI: body mass index; BP: blood pressure; HbA1c: glycated hemoglobin; CRP: C-reactive protein; *values before log transformation (log10). No-Ins: diabetic patients treated with diet and/or anti-diabetic agents; Ins: diabetic patients treated with diet and insulin, with or without anti-diabetic agents; Pearson chi-squared test or unpaired Student’s t-test.

Table 2 - Venous endothelial function by group.

| Parameter                      | No-Ins | Ins | P    |
|--------------------------------|--------|-----|------|
| Venoconstriction (%), phenylephrine | 74.5 ± 8.3 | 72.5 ± 9.2 | 0.566|
| Emax (%), acetylcholine          | 59.3 ± 26.5 | 54.0 ± 16.3 | 0.526|
| Emax (%), sodium nitroprusside   | 113.7 ± 35.3 | 111.9 ± 28.5 | 0.888|
| Drug concentrations              |        |     |      |
| ED70 (ng/min, phenylephrine)     | 50 (25-100) | 100 (25-100) | 0.893|
| Emax (ng/min, acetylcholine)     | 3600 (630-3600) | 3600 (1800-3600) | 0.874|
| Emax (ng/min, sodium nitroprusside) | 371.5 (247.4-495.3) | 247.7 (247.4-495.3) | 0.501|

Data are means ± SDs or medians (25th-75th percentile). Emax: maximum effect; ED70: dose that produced approximately 70% constriction of the vein. Values of drug concentrations are given before log10 transformation.

DISCUSSION

The results of the present study show for the first time that venous endothelial function is similar among type 2 diabetic patients with good metabolic control and well-controlled blood pressure levels, irrespective of their treatment with subcutaneous insulin.

Insulin has known physiological effects upon the vasculature, although the results of studies concerning these effects are discordant. Vasoconstriction and high vascular tone have been described by some authors, while other authors have demonstrated vasodilation induced by insulin infusion. Perhaps these results are discordant because data were obtained from different vascular beds and from different species. In rabbit kidneys, insulin induced afferent arteriolar vasodilation, with no effects upon the efferent artery. In diabetic patients, both regular and lispro insulin promoted the improvement of arterial endothelial function after a meal. Short-term glucose control obtained with insulin and metformin or with insulin only can also induce better arterial endothelial function when compared with the same evaluation performed in hyperglycemic diabetic patients.

The present study was performed in type 2 diabetic patients with good metabolic control, as confirmed by their fasting plasma glucose levels and HbA1c. Their blood pressure levels were also very well controlled. Both hyperglycemia and high blood pressure levels can interfere with endothelial-dependent vasodilation. Although these factors were under control, there was still venous endothelial dysfunction in all of the patients in the group as compared to non-diabetic subjects, who showed 105.8% ± 9.5% of endothelium-dependent vasodilation in a previous study carried out by our group. There were no differences between the groups studied except for the use of insulin, indicating that the subcutaneous use of insulin does not interfere with venous endothelial function, as was previously shown for arterial endothelium evaluation.

Some limitations of this study should be mentioned, such as the small sample size in the Ins group. This group was not easy to recruit due to the necessary characteristics of the patients (i.e., very good glycemic and arterial pressure control). Additionally, because microcirculatory dysfunction is already present in subjects with metabolic syndrome without diabetes and is associated with the adiposity of these individuals, the characteristic inflammatory state of obesity may cause this abnormality; however, insulin resistance and hyperinsulinemia cannot be discarded as possible causes. Although good reproducibility of venous and arterial endothelial function evaluation was previously shown, arteries and veins have different biological activities in terms of the endothelium, probably due to marked regional and segmental heterogeneity in vascular endothelial function. Future studies investigating the association between different vascular beds in response to subcutaneous insulin therapy may introduce new knowledge in this field of investigation.

The present data allow us to conclude that patients with type 2 diabetes treated with diet and anti-diabetic agents have similar venous endothelial function to those patients treated additionally with subcutaneous insulin. Subcutaneous insulin therapy does not interfere with venous endothelial function in type 2 diabetes given stable glycemic and blood pressure control.
AUTHORS’ CONTRIBUTIONS:

AMVS was involved in the conception and design of the study, data collection, data analysis and interpretation, and drafting and editing the final document for publication. LMP was involved in patient selection and data analysis. MCB was involved in data analysis and interpretation. MCI was involved in design of the study, data analysis and interpretation, and writing, drafting and editing of the final document for publication. All authors read and approved the final manuscript.

REFERENCES

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44, doi: 10.2337/diabetes.16.2.434.
2. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:36-52, doi: 10.1210/er.22.1.36.
3. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111-9.
4. Malher K, Anderson TJ, Verma S. Insulin action in the vasculature: physiology and pathophysiology. J Vas Res. 2003;38:415-22, doi: 10.1159/000051074.
5. Kocsis E, Pacher P, Posa I, Nieszner E, Koltai MZ, Pacher P. Hyperglycaemia alters the endothelium-dependent relaxation of canine coronary arteries. Acta Physiol Scand. 2000;169:183-7, doi: 10.1046/j.1365-201x.2000.00731.x.
6. Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N, Braatvedt GD. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J. 2003;31:322-8, doi: 10.1046/j.1445-5994.2000.00727.x.
7. Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D. Simultaneous control of hyperglycaemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care. 2007;30:649-54, doi: 10.2337/diabetes.38.11.S10.
8. Gaerzer H, Neumayr G, Marschang P, Sturm W, Lechleitner M, Foger B, et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol. 2002;89:431-4, doi: 10.1016/S0002-9149(01)02261-4.
9. Vehkavaara S, Yki-Jarvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2004;24:325-30, doi: 10.1161/01.ATV.0000131617.4893.c5.
10. Signorri LU, Vargas da Silva AM, Della Mea Plentz R, Gelsone B, Moreno H, Jr, Bello-Klein A, et al. Reduced venous endothelial responsiveness after oral lipid overload in healthy volunteers. Metabolism. 2008;57:103-9, doi: 10.1016/j.metabol.2007.08.012.
11. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol. 1981;14:237-43.
12. Rebolio ER, Rohde LE, Schaan BD, Rubira MC, Ruschel KB, Plentz RD, et al. Bradykinin or acetylcholine as vasodilators to test endothelial venous function in healthy subjects. Clinics. 2008;63:677-82, doi: 10.1590/S1807-59322008000500017.
13. Silva AM, Signori LU, Plentz RD, Moreno Jr H, Barros E, Bello-Klein A, et al. Hemodialysis improves endothelial venous function in end-stage renal disease. Braz J Med Biol Res. 2008;41:482-8.
14. Schroeder CA, Jr., Chen YL, Messina EJ. Inhibition of NO synthesis or endothelium removal reveals a vasoconstrictor effect of insulin on isolated arterioles. Am J Physiol. 1999;276:H4815-20.
15. Wu HY, Jeng YY, Yue CJ, Chyu KY, Hsieh WA, Chan TM. Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring. Diabetes. 1994;43:1027-32, doi: 10.2337/diabetes.43.8.1027.
16. Chen YL, Messina EJ. Dilation of isolated skeletal muscle arterioles by insulin is endothelium dependent and nitric oxide mediated. Am J Physiol. 1996;270:H1210-4.
17. van Veen S, Chang PC. Prostaglandins and nitric oxide mediate insulin-induced vasodilation in the human forearm. Cardiovasc Res. 1997;34:223-9, doi: 10.1016/S0008-6363(97)00033-X.
18. Juncos LA, Ito S. Disparate effects of insulin on isolated rabbit afferent and efferent arterioles. J Clin Invest. 1993;92:1981-5, doi: 10.1172/JCI116972.
19. Ceriello A, Cavarape A, Martellini L, Da Ros R, Marra G, Quaglia L, et al. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med. 2004;21:171-5, doi: 10.1111/j.1464-5491.2004.01301.x.
20. Forst T, Forst S, Strunk K, Lobig M, Welter K, Kazda C, et al. Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. J Diabetes Complications. 2005;19:128-32, doi: 10.1016/j.jdiacomp.2004.09.002.
21. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146-9, doi: 10.1016/S0735-1097(99)00168-0.
22. Panza JA, Quyummy AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-7, doi: 10.1056/NEJM199007053230210.
23. Antoniades C, Trouillas D, Marinou K, Papageorgiou N, Bosinaou E, Tsioufis C, et al. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clin Cardiol. 2007;30:295-300, doi: 10.1002/clc.20101.
24. Kraemer-Aguilar LG, Laflor CM, Bouskela E. Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metabolism. 2008;57:1740-6, doi: 10.1016/j.metabol.2008.09.034.
25. Silva AM, Schaan BD, Signori LU, Plentz RD, Moreno Jr H, Bertoluci MC, et al. Microalbuminuria is associated with impaired arterial and venous endotheliumdependent vasodilation in patients with type 2 diabetes. J Endocrinol Invest. 2010. (Epub ahead of print).
26. Boegehold MA. Heterogeneity of endothelial function within the circulation. Curr Opin Nephrol Hypertens. 1998;7:77-8.